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Cutaneous melanoma is a tumor with rising incidence and a very poor prognosis at the disseminated stage.
Melanomas are characterized by frequent mutations in BRAF and also by overexpression of fibroblast growth
factor 2 (FGF2), offering opportunities for therapeutic intervention. We investigated inhibition of FGF signaling
and its combination with dacarbazine or BRAF inhibitors as an antitumor strategy in melanoma. The majority of
melanoma cell lines displayed overexpression of FGF2 but also FGF5 and FGF18 together with different isoforms
of FGF receptors (FGFRs) 1–4. Blockade of FGF signals with dominant-negative receptor constructs (dnFGFR1, 3,
or 4) or small-molecule inhibitors (SU5402 and PD166866) reduced melanoma cell proliferation, colony
formation, as well as anchorage-independent growth, and increased apoptosis. DnFGFR constructs also
significantly inhibited tumor growth in vivo. Combination of FGF inhibitors with dacarbazine showed additive
or antagonistic effects, whereas synergistic drug interaction was observed when combining FGFR inhibition
with the multikinase/BRAF inhibitor sorafenib or the V600E mutant-specific BRAF inhibitor RG7204. In
conclusion, FGFR inhibition has antitumor effects against melanoma cells in vitro and in vivo. Combination with
BRAF inhibition offers a potential for synergistic antimelanoma effects and represents a promising therapeutic
strategy against advanced melanoma.
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INTRODUCTION
Melanoma incidence has increased significantly during the
last decades, and despite intensive research, treatment
options at the disseminated stage are still very limited (Gogas
et al., 2007). Mutations in proteins involved in signal
transduction pathways, such as BRAF, NRAS, or CKIT, have
been identified in the majority of melanomas (Ibrahim and
Haluska, 2009), but their exploitation as therapy targets has
only recently started to translate into prolonged patient
survival in clinical settings. Development of additional
treatment options is therefore an urgent requirement to
improve the prognosis of patients with advanced melanoma.
Overexpression of growth and survival-promoting factors
is an important hallmark of neoplastic cells and a major
driving force for tumor progression and dissemination.
Expression of fibroblast growth factor 2 (FGF2) has been
identified as an important characteristic of melanoma cells in
contrast to normal melanocytes (NMs; Halaban et al., 1988)
and has been linked to tumor progression in melanoma and
multiple other malignancies (Jeffers et al., 2002). The role of
other FGFs is widely unexplored in melanoma so far. FGFs
constitute a structurally conserved family of polypeptide
growth factors, with 22 members in humans (Beenken and
Mohammadi, 2009; Powers et al., 2000). FGFs transduce
signals through binding to transmembrane receptor tyrosine
kinases, named FGF receptors (FGFR1–4), and also bind with
lower affinity to heparin-like glycosaminoglycans of the
extracellular matrix (McKeehan et al., 1998). After ligand
binding, FGFRs activate major cellular growth and survival
pathways including, for example, mitogen-activated
protein kinase and phosphoinositide 3-kinase signal cascades
(Acevedo et al., 2009).
Several members of the FGF family have crucial roles in
embryonic and postnatal development and are implicated
in wound healing and tissue maintenance (Powers et al.,
2000). Similar to EGF–receptor, there is also convincing
evidence that hyperactivation of FGFR signaling is associated
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with—and functionally important for—the growth and
progression of several types of human cancer (Jeffers et al.,
2002). In addition to an autocrine effect on tumor cell
survival and proliferation, FGFs also have important roles in
neoangiogenesis, thereby supporting tumor vascularization
and metastasis (Presta et al., 2005).
In the present report, we show that the concomitant
overexpression of several FGF and FGFR family members is a
common feature of human melanoma cells derived from
primary tumors or metastatic lesions. Blockade of FGFR
signals by genetic constructs or specific tyrosine kinase
inhibitors (TKIs) strongly reduces malignant growth of
melanoma cells and synergistically enhances the antimela-
noma effect of BRAF inhibition in vitro and in vivo.
RESULTS
Multiple FGF and FGFR molecules are co-expressed in
melanoma cells
To get a systematic overview of the presence of FGF ligands
and receptors in melanoma cells, we screened the expression
of all 4 FGFR and 22 FGF genes by conventional and real-
time reverse transcription PCR in 12 cell lines from primary
and metastatic melanoma established from surgery speci-
mens. Except for VM47, all cell lines harbored the V600E
mutation of BRAF. The majority of the cell lines expressed all
the four FGFR genes, including both mesenchymal IIIc and
epithelial IIIb isoforms of FGFR1–3 (Figure 1a). Expression of
FGFR1 and 4 was especially prominent. Although FGFR1 was
high in NMs as well, FGFR2 and 4 were upregulated in the
majority of melanoma cell lines (Figure 1b). No obvious
difference was seen between cell lines derived from primary
tumors and those from metastatic lesions. In addition to the
widespread expression of different receptor variants, mela-
noma cell lines also expressed multiple ligands of the FGF
family, suggesting the presence of autocrine signaling loops
(Figure 1c and d, Supplementary Table S1 online). FGF2 was
universally upregulated, reaching more than 100-fold tran-
script levels in 50% of our melanoma cell lines when
compared with NM. FGF5 was almost undetectable in NM
but highly expressed in 6 of 12 melanoma cell lines. No
increase of expression was seen for FGF8 compared with NM
(not shown), and about equal numbers of cell lines displayed
increased and decreased expression of FGF18, another FGF
with oncogenic potential (Sonvilla et al., 2008). Expression of
FGF5, FGF18, and FGFR1 protein was confirmed by
immunofluorescence analysis showing cytoplasmic staining
compatible with transport along the secretory pathway
and comparable to previous results (Figure 1d; Allerstorfer
et al., 2008).
FGFs stimulate growth and migration of melanoma cells
To test whether FGF signals stimulate the neoplastic behavior
of melanoma cells, we investigated the effect of FGF
treatment on cell growth and migration. When VM1, 21,
24, and 48 cells were treated with FGF2, cell growth
increased by 25–50% in all cell lines (Figure 2a). The effect
was strongest in VM48 cells with the lowest endogenous
FGF2 level and weaker in VM24 and VM1, which have 10- to
20-fold higher endogenous FGF2 expression levels than
VM48. Moreover, migration of melanoma cells in transwell
assays was increased upon treatment with a combination of
FGF2 and FGF5 in VM48 cells, whereas in VM24 cells the
same treatment did not reach a significant stimulation of
migration (Figure 2b). These data suggest that FGF signals
enhance growth capacity and migratory potential of mela-
noma cells.
Inhibition of FGF signals inhibits melanoma cell growth in vitro
and in vivo
To determine the dependency of melanoma cells on FGF
signals, we blocked FGFR-mediated signals with adeno-
viruses expressing dominant-negative (dn)FGFR1, 3, and 4.
Expression of dn receptors resulted in up to 50% inhibition in
short-term growth assays (Figure 3a and b; Supplementary
Figure S1a and b online) and was even more pronounced in
clonogenic assays (Supplementary Figure S1c and d online).
The strongest effect was generally seen with dnFGFR1,
whereas dnFGFR3 did not lead to significant inhibition of
growth in any of the cell lines. Transduction with dnFGFR1
also had a very pronounced effect on anchorage-independent
growth, almost completely inhibiting colony formation in soft
agar in three of four cell lines (Figure 3c). Microscopic
examination of VM1 cells after transduction revealed a high
number of rounded-up and detached cells in dnFGFR1—but
not green fluorescent protein (GFP)—transduced cultures
(Supplementary Figure S1e online). Western blotting
revealed processing of caspase-3 and poly(ADP-ribose)
polymerase-1 cleavage in the dnFGFR1-transduced cultures,
thus demonstrating induction of apoptosis by dnFGFR1
expression (Figure 3d). In a xenotransplantation experiment
of VM1 cells, tumor growth was markedly delayed by
dnFGFR1 or dnFGFR4 compared with the GFP control
group (Figure 3e). This resulted in a significantly prolonged
survival of mice carrying the dnFGFR1 xenografts (1.3-fold,
Figure 3f).
FGFR inhibitors enhance the effect of antimelanoma drugs
For clinical application, blockade of FGFR signals with TKIs is
more feasible than the use of dn receptor constructs.
Therefore, we tested the impact of two TKIs inhibiting
FGFR, SU5402, and PD166866 on the melanoma lines
(Figure 4a and b). Both inhibitors reduced cell viability, with
the strongest effect in VM21 (PD166866) and VM24
(SU5402). Only modest effects were seen in the brain
metastasis-derived cell line VM48. The pan-FGFR inhibitor
SU5402 had a higher efficacy than the FGFR1-specific
inhibitor PD166866. As FGF signals have been implicated
in cell survival and chemoresistance, we tested whether
FGFR-specific TKIs could enhance the effect of antimelano-
ma drugs. Addition of SU5402 to dacarbazine, the standard
chemotherapeutic drug used in melanoma, revealed a
statistically significant but modest increase in efficacy only
in VM48 cells (Figure 4c). In contrast, synergistic melanoma
cell growth inhibition was observed for combinations
of FGFR inhibitors with the multikinase/BRAF inhibitor
sorafenib (Figure 4d). In VM48 cells, the FGFR–TKIs alone
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were largely ineffective. Nevertheless, the combination of
sorafenib and PD166866 produced a pronounced effect.
A similar efficacy of PD166866 as in VM21 cells and a
moderate synergism with sorafenib (combination index
(CI): 0.581 at 10mM) was observed also in VM47 cells
harboring wild-type BRAF (not shown). Clonogenic assays
with PD166866 and sorafenib in VM21 cells further
confirmed the synergistic nature of drug interaction (Figure
4e and f).
Combination of PD166866 and sorafenib blocks survival signals
and enhances apoptosis
To shed light on the mechanism underlying the synergism
between FGFR inhibitors and sorafenib, we analyzed the
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Figure 1. Multiple receptor variants and ligands of the fibroblast growth factor/FGF receptor (FGF/FGFR) axis are expressed in melanoma cells. (a) Presence
of all four FGFR transcripts and the different immunoglobulin III-domain isoforms of FGFR1–3 was assessed by reverse transcription PCR in a panel of 12
melanoma cell lines with specific primer pairs. Percentages of cell lines positive for the analyzed transcripts are shown. (b) Expression level of FGFR1–4 and
(c) FGF2, 5, and 18 was analyzed with Taqman assays in melanoma cell lines derived from primary tumor (PT) lymph node (LN) or brain (BR) metastases or
malignant effusion (ME) and in normal melanocytes (NM). (d) Immunofluorescence staining of VM21 and VM24 cells for FGF5, FGF18, and FGFR1. For controls
(Co), primary antibodies were replaced by non-immune serum. Bar¼ 20 mm. dCT, delta threshold cycle.
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effects on downstream signal transduction in VM21 cells
(Figure 5a). As expected, sorafenib alone was sufficient to
abrogate extracellular signal-regulated kinase phosphoryla-
tion, likely via BRAF inhibition. However, only the combina-
tion treatment led to inhibition of phosphorylation of Akt
(acutely transforming retrovirus AKT8 in rodent T-cell
lymphoma) and STAT3, two important mediators of cell
survival. With respect to cell cycle distribution, both drugs
increased the fraction of cells in the G0/G1 phase and
decreased the S-phase population, but the combination did
not further enhance these effects (Figure 5b). Regarding
apoptosis induction, PD166866 alone was not effective at
10 mM but more than doubled the apoptosis-inducing
potential of sorafenib (Figure 5c). These results imply FGFs
as survival factors in melanoma cells and suggest that
increased cell death as a consequence of pronounced
survival pathway inhibition underlies the synergism between
sorafenib and FGFR-targeting agents.
FGFR inhibition enhances efficacy of sorafenib in vivo and
potentiates the activity of the BRAF V600E-specific inhibitor
RG7204
As a next step, we investigated the combination of FGFR
inhibition and sorafenib in vivo in the VM1 human
melanoma xenograft model (Figure 6a). DnFGFR1 alone
again significantly reduced tumor growth (compare with
Figure 3e). In contrast, sorafenib induced only a modest
reduction of tumor growth in the GFP control group.
However, when combined with dnFGFR1, sorafenib further
significantly reduced growth of VM1 xenograft tumors in
severe combined immunodeficient mice.
Finally we tested, whether FGFR inhibition may also
enhance the efficacy of drugs targeting mutated BRAF.
Combination of PD166866 with the V600E BRAF-specific
inhibitor RG7204 (PLX4032) potently reduced clonogenic
growth of VM21 and VM1 cells (Figure 6b and c), suggesting
this combination for further (pre)clinical evaluation as
antimelanoma therapy.
DISCUSSION
During the last decade, molecularly targeted therapies have
revolutionized the treatment of many cancer types and
improved patient survival even in cancers largely resistant
to classical chemotherapy such as hepatocellular carcinoma
(Llovet et al., 2008). In melanoma, FGF2 was identified as an
autocrine growth factor for melanoma cells (Halaban et al.,
1988), and the forced expression of FGF2 was shown to
contribute to a transformed phenotype in melanocytes
(Nesbit et al., 1999). Moreover, inhibition of FGF2 signal
transduction by antisense oligonucleotides or receptor
blockage has confirmed the importance of FGF2/FGFR1 for
melanoma growth in vitro and in vivo (Becker et al., 1992;
Becker et al., 1989; Ozen et al., 2004; Wang and Becker,
1997; Yayon et al., 1997). Despite this important role of FGF-
mediated signals for melanoma development and progres-
sion, no targeting strategies against the FGFR axis have so far
found their way into clinical settings. More recently,
activating mutations in BRAF have attracted much interest
in melanoma and raised hopes for the successful application
of molecularly oriented targeting approaches (Davies et al.,
2002). So far however, clinical trials with the multikinase/
BRAF inhibitor sorafenib have been largely disappointing
(Eisen et al., 2006), and consequently improved targeting
strategies are still eagerly anticipated. The data shown here
demonstrate that inhibition of FGF receptors could be an
important therapeutic approach for melanoma treatment
especially in combination with additional kinase inhibitors.
The expression data from this study are in line with
previous reports showing widespread overexpression of FGF2
in melanoma (Birck et al., 1999; Scott et al., 1991), but also
highlight that a considerable fraction of melanoma cells
express additional FGFs with known oncogenic activity, such
as FGF5 and FGF18 (Allerstorfer et al., 2008; Sonvilla et al.,
2008). Interestingly, these FGFs both contain classical signal
peptides (Beenken and Mohammadi, 2009) and are readily
secreted, whereas FGF2 lacks a signal peptide and was
shown to be partly retained in the cytoplasm, for instance, in
non-small cell lung cancer cells (Berger et al., 1999). Similar
to FGF2, FGF5 also was recently recognized as a potent
inducer of proliferation and tube formation of endothelial
cells (Allerstorfer et al., 2008), and could therefore be an
important player in melanoma cell-induced angiogenesis.
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Figure 2. Fibroblast growth factor (FGF) enhances viability and migration of
melanoma cell lines. (a) Melanoma cells were seeded in 96-well plates and
treated with FGF2 (20 ngml1) in a medium with 5% fetal calf serum (FCS)
for 5 days. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide assay. (b) Melanoma cells were seeded in
transwell chambers in a medium with 5% FCS and treated for 72 hours with
FGF2 or FGF5 (20 ngml1) or a combination of FGF2 and FGF5 (100 ngml1
each, FGF high). Cells that had migrated to the bottom of the lower chamber
were stained with crystal violet and staining quantified with Lucia software.
a, Po0.05 versus untreated control.
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FGF18 expression is controlled by Wnt pathway activity in
colorectal carcinoma (Shimokawa et al., 2003; Sonvilla et al.,
2008) and may be driven by similar mechanisms in
melanoma, where deregulated Wnt signaling has been
described in up to one-third of patients (Larue and Delmas,
2006). On the receptor side, all melanoma cell lines
investigated express multiple FGFR types and isoforms,
enabling them to make use of a wide spectrum of different
ligands with receptor isoform-specific binding affinities
(Zhang et al., 2006). For instance, FGF18 shows only limited
stimulation of FGFR1 IIIc and all IIIb variants but binds with
high affinity to both FGFR3 IIIc and FGFR4 (Zhang et al.,
2006). The latter is strongly expressed in our melanoma cell
lines and was previously found to be associated with reduced
patient survival in melanoma (Streit et al., 2006).
In multiple tumor types, FGF signals have been implicated
in cell survival (Turner and Grose, 2010) and this is
confirmed here by the apoptosis-inducing effect shown for
dnFGFR1. It has been proposed that FGFs may function as
potent rescue signals especially when other signaling
molecules are blocked. For instance, in non-small cell lung
cancer, FGF signals were implicated in intrinsic resistance
against EGFR inhibitors (Kono et al., 2009), and FGFR
inhibitors showed a synergistic activity with the avian
erythroblastosis oncogene B-targeting drugs erlotinib and
lapatinib (Fischer et al., 2008). Similar to these results, we
observed synergistic growth inhibition in our melanoma cell
lines also when combining FGFR inhibitors with erlotinib (not
shown). Stronger synergism, however, was observed in our
study upon combining FGFR inhibitors with sorafenib. This
inhibitor targets BRAF, vascular endothelial growth factor
receptor, and platelet-derived growth factor receptor (Wil-
helm et al., 2004) and has shown therapeutic efficacy in renal
cell and hepatocellular carcinoma (Escudier et al., 2009;
Llovet et al., 2008), leading to its clinical approval for these
malignancies. As BRAF is mutated in over 60% of melanomas
(Davies et al., 2002), sorafenib was considered a promising
agent for melanoma treatment. However, sorafenib showed
no clinical benefit in melanoma when given as single agent
(Eisen et al., 2006); further, the combination with chemother-
apy showed only modest effects (Hauschild et al., 2009;
McDermott et al., 2008). Remarkably, our study also did not
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Figure 3. Dominant-negative (dn) fibroblast growth factor receptor (FGFR) expression inhibits melanoma cell growth in vitro and in vivo, and induces
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reveal any synergism between chemotherapy with dacarba-
zine and FGFR inhibition comparable to recent data on
combination of chemotherapy and FGFR inhibitors in non-
small cell lung cancer (Fischer et al., 2008). These data
suggest that a combination of several kinase inhibitors with
different targets may be more promising in melanoma than a
combination of kinase inhibitors with cytotoxic drugs.
Second-generation inhibitors of BRAF have a higher inhibi-
tory potency especially against the mutated form of BRAF and
have shown increased efficacy in early clinical evaluation
(Tsai et al., 2008; Wellbrock and Hurlstone, 2010). However,
the inhibition of additional BRAF-independent pathways like
the phosphoinositide 3-kinase/AKT pathway may still be
required for efficient cell killing in melanoma cells, as
suggested by studies combining inhibitors of these two
pathways (Smalley et al., 2006; Tran et al., 2008). Our data
showing strong inhibition of Akt and STAT3 phosphorylation
preceding significantly increased apoptosis induction upon
combination of the FGF inhibitor PD166866 and sorafenib
clearly support this hypothesis. The kinase inhibitor RG7204
specifically targeting mutated BRAF has recently shown an
unprecedented response rate of 80% in advanced melanoma
harboring the BRAF mutation (Bollag et al., 2010). Never-
theless, tumor regrowth occurred in many of the patients.
Thus, the authors suggested combination of RG7204
with additional agents as strategy to increase durability of
the response. The synergistic potential of combining RG7204
with PD166866 observed in this study indicates that
inhibition of the universally hyperactivated FGFR system,
which feeds into several major survival pathways, in
combination with the targeted blockade of a tumor-specifi-
cally activated downstream pathway may represent a
promising approach for melanoma therapy.
In summary, our data highlight the importance of the FGF/
FGFR axis as significant therapeutic target in melanoma and
suggest that especially the combination of FGFR blockade
with BRAF inhibition may offer a considerable potential for
synergistic antitumor effects.
MATERIALS AND METHODS
Chemicals
The FGFR1-specific inhibitor PD166866 (Panek et al., 1998) was
supplied by Pfizer (Groton, CT). The pan-FGFR inhibitor SU5402 was
obtained from Calbiochem (La Jolla, CA), sorafenib from LC Labora-
tories (Woburn, MA), and RG7204 from Selleck Chemicals (Houston,
TX). Recombinant human FGF2 was from Chemicon International
(Temecula, CA) and FGF5 from Strathmann Biotec AG (Hamburg,
Germany). All other reagents were from Sigma (St Louis, MO).
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Figure 4. Fibroblast growth factor receptor (FGFR) kinase inhibitors reduce melanoma cell growth and show synergism with sorafenib. Melanoma cells were
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Cell culture
Twelve cell lines have been established from surgical specimens of
primary melanoma (VM7, VM10, VM21, VM23, and VM30) or
metastatic melanoma from lymph node (VM1, VM8, and VM24) or
brain (VM28, VM47, and VM48; Pirker et al., 2003). One cell line
(VM31) was derived from a malignant effusion. Histopathologically,
cell lines were derived from superficial spreading melanoma (SSM;
VM1 and VM10), nodular melanoma (VM7þ 8, VM21þ 23, VM24,
VM30, VM31, VM47, and VM48), mixed SSM/NM histology
(VM30), or unknown subtype of the primary tumor (VM28). Cells
were grown in RPMI medium with 10% fetal calf serum at 37 1C in a
humidified atmosphere containing 5% CO2. Cells were authenti-
cated using microsatellite marker analysis and regularly checked for
mycoplasma contamination.
Real-time reverse transcription PCR
Total RNA was extracted from 106 cells with TRIzol reagent
(Invitrogen, Carlsbad, CA) and reverse transcription, PCR and Taqman
analyses were performed as published (Grusch et al., 2006). RNA
from normal human epidermal neonatal melanocytes (Lonza, Basel,
Switzerland) as non-malignant cell counterparts was used for
comparison. Primer sequences and Taqman assay IDs are given in
Supplementary Table S2 and S3 online. For normalization, threshold
cycle (Ct) values of 18S were subtracted from the Ct values of the
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Figure 6. Fibroblast growth factor receptor (FGFR) inhibition enhances
efficacy of sorafenib (Sor) in vivo and shows synergism with RG7204.
(a) VM1 cells transduced with dominant-negative (dn)FGFR1 or green
fluorescent protein (GFP) adenovirus were injected into severe combined
immunodeficient mice (eight per group) and treated with Sor or solvent during
the indicated period. b, Po0.01 versus GFP Sor, dnFGFR1 control (Co).
Clonogenic assays of VM21 (b) and VM1 (c) cells treated with 1 mM PD166866
(PD) and 0.1 mM RG7204 (RG) for 14 days. For VM21 cells, the combination
index (CI) value indicating synergism is shown. For VM1 cells, inefficacy of
1mM PD166866 alone precluded calculation of a CI value and P-values for
reduction of clonal growth are shown instead. a, Po0.05 versus RG; b,
Po0.01 versus PD.
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Figure 5. Combination of fibroblast growth factor receptor (FGFR)
inhibition with sorafenib treatment blocks survival signals and enhances
apoptosis. (a) VM21 cells were treated with 10 mM PD166866 (PD), 10 mM
sorafenib (Sor), or a combination of both agents in medium with 5% fetal calf
serum for 6 hours. Cell lysates were immunoblotted with the indicated
antibodies, and representative blots of at least three different experiments are
shown (b) VM21 cells were treated as above for 18 hours and analyzed by
flow cytometry. Means and SD of duplicates from two experiments are
shown. (c) Cells were treated as above for 48 hours, and percentages of viable
and apoptotic cells were determined after staining with Hoechst 33258 and
propidium iodide. Values represent means and SD of duplicates from two
experiments. Co, control; ERK, extracellular signal-regulated kinase;
pAKT, phosphorylated acutely transforming retrovirus AKT8 in rodent T cell
lymphoma; pERK, phosphorylated extracellular signal-regulated kinase;
pSTAT3, phosphorlylated signal transducer and activator of transcription 3.
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respective FGFR/FGF genes and the resulting delta Ct (dCt) values
transformed to relative expression levels by the formula 2(dCt) 105.
Immunofluorescence
Cells were grown on collagen-coated microscope slides in
quadriperm chambers (Sigma) and fixed with methanol/acetone
(3:1) for 10minutes at 20 1C. Cells were incubated with primary
antisera (anti-FGFR1, anti-FGF18 (Santa Cruz Biotechnology
(Santa Cruz, CA), sc-121, and sc-16830), anti-FGF5 (R&D Systems
(Minneapolis, MN), AF-237 NA) diluted 1:25 in phosphate-buffered
saline with 1% BSA) for 1 hour, followed by FITC- or Cy3-coupled
secondary antibodies (1:500, Jackson Laboratories, West Grove, PA).
Cells were counterstained with TOPRO3, mounted in Mowiol
(Sigma), and photographed on a Leica TCS-SP confocal microscope
(Leica Microsystems, Wetzlar, Germany).
In vitro assays
For cytotoxicity assays, exponentially growing cells were seeded into
96-well plates at a density of 2 103 cells per well in 100 ml medium
containing 10% fetal calf serum. At 24 hours later, another 100ml
serum-free medium containing FGF2, FGF5, or the indicated drugs
were added. Controls were vehicle-treated only. Cell viability was
assessed by MTT assay (EZ4U, Biomedica, Vienna, Austria). Five
wells were analyzed per treatment condition, and experiments were
repeated at least three times. Effects of drug combinations were
analyzed by exposing tumor cells in parallel to the two investigated
drugs as single agents and in combination. CI values indicating
additive (0.9oCIo1.1), antagonistic (CI41.1), or synergistic
(CIo0.9) drug interaction were calculated with Calcusyn software
(Biosoft, Cambridge, UK; Chou and Talalay, 1984). For clonogenic
assays, 1.25 102 cells cm2 were exposed to viral constructs or
drugs for 14 days. Clones were stained with crystal violet and CI
values calculated as above. For details on additional in vitro assays,
see Supplementary Materials and Methods online.
DnFGFR adenoviruses
Adenoviral expression vectors for dnFGFR1 and dnFGFR3 have been
described previously (Fischer et al., 2008; Sonvilla et al., 2010).
A plasmid encoding human FGFR4 cDNA was kindly provided by
S Ezzat. To generate a kinase-truncated dn variant, the FGFR4 open
reading frame was subcloned into pENTR1A (Invitrogen, Carlsbad,
CA) with KpnI/XhoI and the kinase domain removed by digestion
with BglII/NotI and replaced with the likewise digested cyan
fluorescent protein sequence. The resulting FGFR4–cyan fluorescent
protein chimera was transferred into pAd/CCMV/V5-Dest by Gate-
way recombination (Invitrogen). Virus amplification was done as
described and an adenovirus-expressing GFP was used as control
(Losert et al., 2006). Virus titers were determined with the Adeno-X
Rapid Titer Kit (Clontech, Mountain View, CA).
Western blot analysis
Western blotting and immunodetection were done as described
(Sonvilla et al., 2008). For details, see Supplementary Materials and
Methods online.
Tumor formation in severe combined immunodeficient mice
Cells were transduced with dnFGFR1, dnFGFR4, or GFP adenovirus
on cell culture plates. Subsequently, 106 cells in 50 ml phosphate-
buffered saline were subcutaneously injected into the rear flanks of
severe combined immunodeficient BALB/c recipient mice (female,
age 4 weeks; Harlan Winkelmann, Borchen, Germany). In one
experiment, animals were treated orally with sorafenib (2.5mg kg1
in cremophor EL) or solvent five times a week for 2 weeks starting
from day 34 after injection. Tumor size was determined using a
vernier caliper and used for calculation of tumor volume (smaller
diameter2 larger diameter 0.5). Animals were killed when
tumors exceeded a volume of 5,000mm3. Experiments were carried
out according to the Austrian and FELASA guidelines for animal care
and protection.
Statistical analysis
Unless stated otherwise, data are presented as means and SD of at
least three experiments. Statistical significance between treatments
was analyzed with GraphPad Prism software using Student’s t-test or
one- or two-way analysis of variance for comparison of two or
multiple groups, respectively. Survival analysis was performed using
Kaplan–Meier curves and log-rank test. In all cases, Pp0.05 was
considered statistically significant.
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